Sertindole in schizophrenia: efficacy and safety issues

Bibliography

• Kane J, Mayerhoff D. Do negative symptoms respond to pharmacologic treatment? Br J Psychiatry 1989;55(Suppl 7):115-18
   Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008;101(1-3):273-86
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Holcomb HH. Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 2005;10(1):27-39
   PubMed Web of Science ®Google Scholar
• Bell MD, Corbera S, Johannesen JK, et al. Social cognitive impairments and negative symptoms in schizophrenia: are there subtypes with distinct functional correlates? Schizophr Bull 2013;39(1):186-96
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Leucht S. Clozapine resistance-augmentation strategies. Eur Neuropsychopharmacol 2013;23:338
   PubMedGoogle Scholar
• Muscatello MR, Pandolfo G, Micò U, et al. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014;34:129-33
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 2011;127:93-9
   PubMed Web of Science ®Google Scholar
• Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007;93:109-16
   PubMed Web of Science ®Google Scholar
• Muscatello M, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol 2011;25:667-74
   PubMed Web of Science ®Google Scholar
• Mico’ U, Bruno A, Pandolfo G, et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011;26:303-10
   PubMed Web of Science ®Google Scholar
• Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 2002;6:S3-9
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother 2006;7:1825-34
   PubMed Web of Science ®Google Scholar
• Pae CU. Sertindole: dilemmas for its use in clinical practice. Expert Opin Drug Saf 2013;12(3):321-6
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Mack RJ, Granneman R, et al. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997;12(Suppl 1):S29-35
   PubMedGoogle Scholar
• Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol 1998;13(Suppl 3):S65-70
   PubMedGoogle Scholar
• Kasper S. Sertindole: safety and tolerability profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S27-32
   PubMedGoogle Scholar
• Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30
   PubMed Web of Science ®Google Scholar
• Cincotta SL, Rodefer JS. Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr Dis Treat 2010;6:429-41
   PubMed Web of Science ®Google Scholar
• Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol 2008;4:629-38
   PubMed Web of Science ®Google Scholar
• Muscatello MRA, Bruno A, Pandolfo G, et al. Emerging treatments in the management of schizophrenia. Focus on sertindole. Drug Des Devel Ther 2010;4:187-201
   PubMed Web of Science ®Google Scholar
• Azorin JM, Kaladjian A, Fakra E, Adida M. Sertindole for the treatment of schizophrenia. Expert Opin Pharmacother 2010;11(18):3053-64
   PubMed Web of Science ®Google Scholar
• Karamatskos E, Lambert M, Mulert C, Naber D. Drug safety and efficacy evaluation of sertindole for schizophrenia. Expert Opin Drug Saf 2012;11(6):1047-62
   PubMed Web of Science ®Google Scholar
• Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmachological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101
   PubMed Web of Science ®Google Scholar
• Hyttel L, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5-HT2, D2 and alpha one receptors. J Neural Transm 1992;89:61-9
   PubMed Web of Science ®Google Scholar
• Mørk A, Witten LM, Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl) 2009;206:39-49
   PubMed Web of Science ®Google Scholar
• Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992;10:25-32
   PubMed Web of Science ®Google Scholar
• Hietala J, Kuoppamaki M, Majasuo H, et al. Sertindole is a serotonin 5-HT2C inverse agonist and decreases agonist but not antagonist binding to 5-HT2C receptors after chronic treatment. Psychopharmacology (Berl) 2001;157:180-7
   PubMed Web of Science ®Google Scholar
• Petit-Taboué MC, Landeau B, Barré L, et al. Parametric PET imaging of 5-HT2A receptor distribution with 18F-setoperone in the normal human cortex. J Nucl Med 1999;40:25-32
   PubMed Web of Science ®Google Scholar
• Nyberg S, Olsson H, Nilsson U, et al. Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 2002;162:37-41
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Haznedar M, Newmark RE, et al. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr Res 2009;114:161-71
   PubMed Web of Science ®Google Scholar
• Wong SL, Linen P, Mack RJ, Granneman GR. Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos 1997;18:533-41
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006;187:415-23
   PubMed Web of Science ®Google Scholar
• Wong SL, Cao G, Mack RJ, Granneman GR. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997;62:157-64
   PubMed Web of Science ®Google Scholar
• Wong SL, Menacherry S, Mulford D, et al. Parmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997;52:223-7
   PubMed Web of Science ®Google Scholar
• Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol 1997;37(11):1056-61
   PubMedGoogle Scholar
• Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-75
   PubMed Web of Science ®Google Scholar
• Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997;154:782-91
   PubMed Web of Science ®Google Scholar
• Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 2000;4:55-62
   PubMed Web of Science ®Google Scholar
• Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998;34:61-9
   PubMed Web of Science ®Google Scholar
• Hale AS, Azorin JM, Lemming OM, Mæhlum E. Sertindole in the long-term treatment of schizophrenia. Int Clin Psychopharmacol 2012;27(4):231-7
   PubMed Web of Science ®Google Scholar
• Azorin JM, Murteira S, Hansen K, Toumi M. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis. BMC Psychiatry 2008;8:16
   PubMedGoogle Scholar
• Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006;21:49-56
   PubMed Web of Science ®Google Scholar
• Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. J Clin Psychiatry 2011;72(2):194-204
   PubMed Web of Science ®Google Scholar
• Kwon JS, Mittoux A, Hwang JY, et al. The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study. Int Clin Psychopharmacol 2012;27(6):326-35
   PubMed Web of Science ®Google Scholar
• Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 2012;32:173-8
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
   PubMed Web of Science ®Google Scholar
• Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 2008;33:2657-66
   PubMed Web of Science ®Google Scholar
• Goetghebeur P, Dias R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study. Psychopharmacology (Berl) 2009;202:287-93
   PubMed Web of Science ®Google Scholar
• Didriksen M, Skarsfeldt T, Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris’ water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 2007;193:225-33
   PubMed Web of Science ®Google Scholar
• Broberg BV, Glenthøj BY, Dias R, et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia-sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl) 2009;206(4):631-40
   PubMedGoogle Scholar
• Idris N, Neill J, Grayson B, et al. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) 2010;208:23-36
   PubMed Web of Science ®Google Scholar
• Mutlu O, Ulak G, Celikyurt IK, et al. Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice. Pharmacol Biochem Behav 2011;99(4):557-65
   PubMedGoogle Scholar
• Nikiforuk A, Popik P. Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats. Psychopharmacology (Berl) 2012;220(1):65-74
   PubMed Web of Science ®Google Scholar
• Gallhofer B, Jaanson P, Mittoux A, et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-86
   PubMed Web of Science ®Google Scholar
• Buchsbaum MS, Haznedar M, Newmark RE, et al. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr Res 2009;114:161-71
   PubMed Web of Science ®Google Scholar
• Holstein DH, Csomor PA, Geyer MA, et al. The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. J Psychopharmacol 2011;25(12):1600-13
   PubMed Web of Science ®Google Scholar
• Nielsen RE, Levander S, Thode D, Nielsen J. Effects of sertindole on cognition in clozapine-treated schizophrenia patients. Acta Psychiatr Scand 2012;126(1):31-9
   PubMedGoogle Scholar
• Nielsen RE, Odur F, Ostergaard T, et al. Comparison of the effects of Sertindole and Olanzapine on Cognition (SEROLA): a double-blind randomized 12-week study of patients diagnosed with schizophrenia. Ther Adv Psychopharmacol 2014;4(1):4-14
   PubMedGoogle Scholar
• Perquin LN, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30
   PubMed Web of Science ®Google Scholar
• Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005(3):CD001715
   PubMedGoogle Scholar
• De Hert M, Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci 2011;261:231-9
   PubMedGoogle Scholar
• Beach SR, Celano CM, Noseworthy PA, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013;54(1):1-13
   PubMed Web of Science ®Google Scholar
• Witchel HJ, Hancox JC. Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 2000;27:753-66
   PubMed Web of Science ®Google Scholar
• Haverkamp W, Eckhardt L, Matz J, Frederiksen K. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002;6:11-20
   PubMed Web of Science ®Google Scholar
• Eckardt L, Breithardt G, Haverkamp W. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsades de pointes: low torsadogenic potential despite QT prolongation. J Pharmacol Exp Ther 2002;300:64-71
   PubMed Web of Science ®Google Scholar
• Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19:702-7
   PubMed Web of Science ®Google Scholar
• Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121:385-8
   PubMed Web of Science ®Google Scholar
• Hertz S. NDA file. 2010. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrug Safety Information for Patients and Providers/UCM234349.pdf
   Google Scholar
• Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in postmarketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6
   PubMed Web of Science ®Google Scholar
• Peuskens J, Moore N, Azorin JM, et al. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007;16:804-11
   PubMed Web of Science ®Google Scholar
• Kasper S, Möller H-J, Hale A. The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment. Eur Arch Psychiatry Clin Neurosci 2010;260:59-68
   PubMed Web of Science ®Google Scholar
• Lançon C, Toumi M, Sapin C, Hansen K. The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe. BMC Psychiatry 2008;8:57
   PubMed Web of Science ®Google Scholar
• Thomas SHL, Drici MD, Hall GC, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 2010;122:345-55
   PubMed Web of Science ®Google Scholar
• Muldoon C, Cochran J. Mortality rates in three comparative cohorts of patients who received sertindole, olanzapine or risperidone: a hospital-based, retrospective study. J Outcomes Res 2006;10:47-55
   Google Scholar
• Crocq MA, Naber D, Lader MH, et al. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol 2010;20:829-38
   PubMed Web of Science ®Google Scholar
• Launois R, Graf von der Schulenburg MG, Knapp M, Toumi M. Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model. Int J Psychiatry Clin Pract 1998;2(Suppl 2):S79-86
   PubMedGoogle Scholar
• Lindström E, Eberhard J, Fors BM, et al. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry 2011;65:403-13
   PubMed Web of Science ®Google Scholar
• Sonntag M, König HH, Konnopka A. The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review. Pharmacoeconomics 2013;31:1131-54
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2013;18:53-66
   PubMed Web of Science ®Google Scholar
• H. Lundbeck A/S. Sertindole: summary of product characteristics. H. Lundbeck A/S, Copenhagen; 2005
   Google Scholar
• Cleghorn JM, Kaplan RD, Szechtman B, et al. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 1990;3:211-19
   PubMed Web of Science ®Google Scholar
• Iasevoli F, Tomasetti C, Marmo F, et al. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berl) 2010;212:329-44
   PubMedGoogle Scholar
• Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82
   PubMed Web of Science ®Google Scholar